Summary of key recommendations: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 4: | Line 4: | ||
==Summary of Key Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults== | ==Summary of Key Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults== | ||
A. Heart-healthy lifestyle habits should be encouraged for all individuals | ===A. Heart-healthy lifestyle habits should be encouraged for all individuals=== | ||
===B. The appropriate intensity of statin therapy should be initiated or continued=== | |||
{|class="wikitable" style="width:80%" | {|class="wikitable" style="width:80%" | ||
|- | |- | ||
| Line 24: | Line 25: | ||
*Re-emphasize heart-healthy lifestyle habits and address other risk factors | *Re-emphasize heart-healthy lifestyle habits and address other risk factors | ||
** ‡7.5% 10-y ASCVD risk: Moderate- or high-intensity statin ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' <nowiki>"</nowiki> | ** ‡7.5% 10-y ASCVD risk: Moderate- or high-intensity statin ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' <nowiki>"</nowiki> | ||
|} | |} | ||
Revision as of 18:12, 27 October 2016
Template:Hypercholesterolemia Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Summary of Key Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults
A. Heart-healthy lifestyle habits should be encouraged for all individuals
B. The appropriate intensity of statin therapy should be initiated or continued
| Class I |
"1.Clinical ASCVD which includes acute coronary syndromes, history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic origin (Level of Evidence: A) "
|
"2.Primary prevention – Primary LDL-C ‡190 mg/dL (Level of Evidence: B) "
|
"3.Primary preventiondDiabetes 40–75 years of age and LDL-C 70–189 mg/dL (Level of Evidence: A) "
|
"4. Primary prevention – No diabetes 40–75 years of age and LDL-C 70–189 mg/dL (Level of Evidence: C) "
|
| Class III (Harm) |
| "1. RECOMMENDATION 1 HERE (Level of Evidence: C)" |
| "2. RECOMMENDATION 2 HERE (Level of Evidence: C)" |
| Class III (No Benefit) |
| "1. RECOMMENDATION 1 HERE (Level of Evidence: C)" |
| "2. RECOMMENDATION 2 HERE (Level of Evidence: C)" |
| Class IIa |
| "1. RECOMMENDATION 1 HERE (Level of Evidence: C)" |
| "2. RECOMMENDATION 2 HERE (Level of Evidence: C)" |
| Class IIb |
| "1. RECOMMENDATION 1 HERE (Level of Evidence: C)" |
| "2. RECOMMENDATION 2 HERE (Level of Evidence: C)" |